insights_auto
Why is AXGN up 2,64%?
Dive Deeperchevron_right
AXGN:NASDAQ
AxoGen, Inc Common Stock
36,17 $
arrow_upward
+2,64%(+0,93) 1D
36,17 $
0,00% (0,00)
bedtimeAfter hours
Closed: 20 հոկ, 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
35,71 $
High
36,84 $
Low
35,56 $
Mkt. cap
2,12 մլրդ
Avg. vol.
1,50 մլն
Volume
973,67 հզր
52-wk high
52,91 $
52-wk low
16,78 $
EPS
-0,68 $
Beta
1,17
Shares outstanding
58,67 մլն
No. of employees
622
Open
35,71 $
High
36,84 $
Low
35,56 $
Mkt. cap
2,12 մլրդ
Avg. vol.
1,50 մլն
Volume
973,67 հզր
52-wk high
52,91 $
52-wk low
16,78 $
EPS
-0,68 $
Beta
1,17
Shares outstanding
58,67 մլն
No. of employees
622
News stories
From web sources and news partners
www.marketscreener.com
·
38 րոպե առաջ
Rapid7 Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
·
1 ժամ առաջ
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in The Ensign Group, Inc. (NASDAQ: ENSG) to Contact Law Firm
FinancialContent
·
28 րոպե առաջ
QCR Holdings (NASDAQ:QCRH) Reports Sales Below Analyst Estimates In Q3 2026 Earnings
Seeking Alpha
·
32 րոպե առաջ
3 things to look out for on Wednesday
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersAlachua, Ֆլորիդա, Միացյալ Նահանգներ
Sector-
Websiteaxogeninc.com